Overview
My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.
Current Appointments & Affiliations
Recent Publications
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Journal Article Clin Cancer Res · February 17, 2026 PURPOSE: Low-grade serous ovarian carcinoma (LGSOC) is a distinct form of ovarian cancer characterized by younger patient age and relative chemoresistance. The GOG281/LOGS trial (NCT02101788) investigated the efficacy of the MEK inhibitor trametinib compar ... Full text Link to item CiteA phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer.
Journal Article Int J Gynecol Cancer · December 13, 2025 OBJECTIVE: Weekly dose-dense paclitaxel may have immunomodulatory effects, enhancing immune responses via cytotoxic T-cell infiltration. Therefore, we assessed the combination of weekly dose-dense paclitaxel with pembrolizumab in patients with platinum-res ... Full text Link to item CiteAdvancing physician-scientist career development in obstetrics and gynecology: 40 years of the American Association of Obstetricians and Gynecologists Foundation scholar program.
Journal Article Am J Obstet Gynecol · December 2025 Full text Link to item CiteRecent Grants
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Clinical TrialPrincipal Investigator · Awarded by Genmab US, Inc. · 2026 - 2031A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline LLC · 2025 - 2030A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Pr
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2025 - 2030View All Grants